XBiotech (XBIT) Cash from Operations (2014 - 2025)

XBiotech has reported Cash from Operations for 12 years, with the latest figure at -$23.0 million in Q4 2025.

• On a quarterly basis, Cash from Operations fell 250.95% year-over-year to -$23.0 million in Q4 2025; TTM through Dec 2025 was -$39.9 million, a 28.93% decrease from a year earlier, with the FY2025 full-year figure at -$39.9 million, down 28.93% from the prior year.
• Cash from Operations was -$23.0 million for Q4 2025 at XBiotech, down from -$4.3 million in the prior quarter.
• The five-year high for Cash from Operations was $72.8 million in Q2 2021, with the low at -$23.0 million in Q4 2025.
• Average Cash from Operations over 5 years is -$1.7 million, with a median of -$5.0 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2022: Cash from Operations soared 729.3% in 2021, then tumbled 383.2% in 2022.
• Over 5 years, Cash from Operations stood at -$1.8 million in 2021, then sank by 79.87% to -$3.2 million in 2022, then retreated by 8.5% to -$3.4 million in 2023, then tumbled by 90.5% to -$6.5 million in 2024, then plunged by 250.95% to -$23.0 million in 2025.
• The last three Cash from Operations figures came in at -$23.0 million (Q4 2025), -$4.3 million (Q3 2025), and -$6.0 million (Q2 2025), per Business Quant data.